Results from a phase 3 clinical trial fell short of expectations but exhibited beneficial effects on other outcomes that could have supplemented its primary endpoint. Integrating these other outcomes into a single analysis led to a deeper understanding of the treatment effect and its significant impact on some patient subgroups. This newly discovered potential of the treatment was used as a central point in the design of a new phase 3 trial.